Kennen MacKay
Stock Analyst at RBC Capital
(2.22)
# 2,529
Out of 4,789 analysts
39
Total ratings
46.15%
Success rate
7.36%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kennen MacKay
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NUVB Nuvation Bio | Maintains: Outperform | $4 → $5 | $1.76 | +184.09% | 1 | Apr 17, 2024 | |
| AGIO Agios Pharmaceuticals | Maintains: Outperform | $40 → $42 | $29.30 | +43.34% | 3 | Jun 27, 2023 | |
| AMGN Amgen | Maintains: Sector Perform | $224 → $236 | $311.55 | -24.25% | 4 | Aug 5, 2022 | |
| EXEL Exelixis | Maintains: Outperform | $32 → $31 | $36.92 | -16.03% | 2 | Nov 3, 2021 | |
| ADCT ADC Therapeutics | Maintains: Outperform | $33 → $34 | $1.41 | +2,311.35% | 2 | Nov 3, 2021 | |
| PRTA Prothena Corporation | Maintains: Outperform | $59 → $82 | $12.38 | +562.63% | 5 | Sep 30, 2021 | |
| PBYI Puma Biotechnology | Maintains: Sector Perform | $13 → $6 | $2.96 | +102.70% | 2 | Aug 6, 2021 | |
| BMRN BioMarin Pharmaceutical | Maintains: Sector Perform | $87 → $88 | $70.69 | +24.49% | 9 | Jul 29, 2021 | |
| NRIX Nurix Therapeutics | Initiates: Outperform | $42 | $11.88 | +253.54% | 1 | Apr 30, 2021 | |
| MESO Mesoblast | Initiates: Sector Perform | $48 | $12.48 | +284.62% | 1 | Oct 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $275 → $175 | $4.76 | +3,576.47% | 2 | May 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $18 → $23 | $42.09 | -45.36% | 3 | Apr 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | n/a | $18.59 | - | 3 | Apr 4, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $210 | $3.74 | +5,514.97% | 1 | Sep 15, 2017 |
Nuvation Bio
Apr 17, 2024
Maintains: Outperform
Price Target: $4 → $5
Current: $1.76
Upside: +184.09%
Agios Pharmaceuticals
Jun 27, 2023
Maintains: Outperform
Price Target: $40 → $42
Current: $29.30
Upside: +43.34%
Amgen
Aug 5, 2022
Maintains: Sector Perform
Price Target: $224 → $236
Current: $311.55
Upside: -24.25%
Exelixis
Nov 3, 2021
Maintains: Outperform
Price Target: $32 → $31
Current: $36.92
Upside: -16.03%
ADC Therapeutics
Nov 3, 2021
Maintains: Outperform
Price Target: $33 → $34
Current: $1.41
Upside: +2,311.35%
Prothena Corporation
Sep 30, 2021
Maintains: Outperform
Price Target: $59 → $82
Current: $12.38
Upside: +562.63%
Puma Biotechnology
Aug 6, 2021
Maintains: Sector Perform
Price Target: $13 → $6
Current: $2.96
Upside: +102.70%
BioMarin Pharmaceutical
Jul 29, 2021
Maintains: Sector Perform
Price Target: $87 → $88
Current: $70.69
Upside: +24.49%
Nurix Therapeutics
Apr 30, 2021
Initiates: Outperform
Price Target: $42
Current: $11.88
Upside: +253.54%
Mesoblast
Oct 22, 2020
Initiates: Sector Perform
Price Target: $48
Current: $12.48
Upside: +284.62%
May 8, 2020
Maintains: Outperform
Price Target: $275 → $175
Current: $4.76
Upside: +3,576.47%
Apr 3, 2019
Upgrades: Outperform
Price Target: $18 → $23
Current: $42.09
Upside: -45.36%
Apr 4, 2018
Downgrades: Sector Perform
Price Target: n/a
Current: $18.59
Upside: -
Sep 15, 2017
Initiates: Outperform
Price Target: $210
Current: $3.74
Upside: +5,514.97%